NPM::ALK TRANSCRIPT LEVELS AND ANTI-ALK AUTOANTIBODY TITERS AS BIOMARKERS FOR OUTCOME IN PEDIATRIC ALK+ ANAPLASTIC LARGE CELL LYMPHOMA TREATED WITH BRENTUXIMAB VEDOTIN OR CRIZOTINIB IN COMBINATION WITH CHEMOTHERAPY: COG ANHL12P1

IF 2.2 4区医学 Q3 HEMATOLOGY

Leukemia research Pub Date : 2025-09-01 DOI:10.1016/j.leukres.2025.107983

Christopher J. Forlenza, David J. Hoogstra, Lauren Saguilig, Donald A. Barkauskas, Suzanne D. Turner PhD, Nina Prokoph PhD, Perla Pucci PhD, Lucy Hare MD PhD, Leila Jahangiri PhD, Rui Wu, Kojo S. Elenitoba-Johnson, Eric J. Lowe, Megan S. Lim

引用次数: 0

查看原文本刊更多论文

Npm:: alk转录物水平和抗alk自身抗体滴度是brentuximab vedotin或crizotinib联合化疗治疗儿童alk +间变性大细胞淋巴瘤预后的生物标志物：cog和hl12p1

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Leukemia research 医学-血液学

CiteScore

4.00

自引率

3.70%

发文量

259

审稿时长

1 months

期刊介绍： Leukemia Research an international journal which brings comprehensive and current information to all health care professionals involved in basic and applied clinical research in hematological malignancies. The editors encourage the submission of articles relevant to hematological malignancies. The Journal scope includes reporting studies of cellular and molecular biology, genetics, immunology, epidemiology, clinical evaluation, and therapy of these diseases.